Related Experiment Video
Updated: Jun 17, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.7K
Remote levodopa challenge test in Parkinson's disease: Feasibility, reliability, validity and economic value
Zhitong Zeng1, Zhengyu Lin1, Zhonglue Chen2
1Department of Neurosurgery, Centre for Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
European Journal of Neurology
|August 8, 2024
Summary
An in-home remote levodopa challenge test (LCT) for Parkinson's disease (PD) patients is feasible, reliable, and valid. This remote LCT significantly reduces healthcare costs for patients with PD.
Area of Science:
- Neurology
- Digital Health
- Clinical Trials
Background:
- Parkinson's disease (PD) management requires accurate assessment of levodopa response.
- Traditional in-hospital testing presents logistical and financial challenges for patients with PD (PwPD).
- Remote, technology-enabled healthcare solutions are increasingly important for chronic disease management.
Purpose of the Study:
- To establish the feasibility, reliability, and validity of an in-home remote levodopa challenge test (LCT) for PwPD.
- To assess the performance of a remote LCT delivered via an online platform.
- To evaluate the potential cost savings associated with a remote LCT.
Main Methods:
- A sequential, comparative study design was employed, comparing in-home remote LCT with in-hospital standard LCT in PwPD.
- Participants underwent both testing methods, separated by approximately three weeks.
- Levodopa responsiveness was assessed using a modified Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III, with reliability and validity determined by intraclass correlation and Pearson's correlation coefficients, respectively.
Main Results:
- Eighty out of 106 screened PwPD (75.5%) successfully completed both remote and standard LCT protocols.
- The remote LCT demonstrated good reliability (Intraclass Correlation Coefficient = 0.81) and strong concurrent validity (r = 0.84) when compared to the standard LCT.
- The estimated mean cost reduction for PwPD utilizing the remote LCT was substantial, at 91%.
Conclusions:
- The in-home remote levodopa challenge test (LCT) is a feasible, reliable, and valid method for assessing levodopa responsiveness in patients with Parkinson's disease.
- This remote approach offers significant potential to reduce healthcare-related expenses for PwPD and their caregivers.
- The findings support the integration of digital health tools into routine Parkinson's disease care.
Related Concept Videos
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:15Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508